In this educational activity, faculty members Nina Delaney Wagner-Johnston, MD, and Seema A. Bhat, MD, review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or relapsed/refractory (R/R) CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.
